<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654312</url>
  </required_header>
  <id_info>
    <org_study_id>HCTox</org_study_id>
    <nct_id>NCT04654312</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität des Saarlandes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is designed as a national, prospective, single-center, double-blind,&#xD;
      parallel group, randomized, controlled, interventional trial to investigate whether a therapy&#xD;
      with HCT compared with placebo can affect dermal photosensitivity and DNA stability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previously published retrospective analyses leading to the official warning about the use of&#xD;
      hydrochlorothiazide (HCT).&#xD;
&#xD;
      The underlying pilot study examins, if the intake of HCT leads to increased dermal&#xD;
      photosensitivity and in combination with UV-exposition to a DNA-damage of the skin.&#xD;
&#xD;
      Up until today, there is no prospective, randomized, placebo-controlled trial investigating&#xD;
      the impact of HCT on dermal photosensitivity in greater detail. The pilot trial is designed&#xD;
      as feasibility study to clarify the impact of HCT on dermal photosensitivity. This may&#xD;
      facilitate evidence-based recommendations as to whether or not HCT increases the risk for&#xD;
      skin cancer. Of note, HCT is one of most frequently prescribed drugs in Germany.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Actual">July 22, 2021</completion_date>
  <primary_completion_date type="Actual">July 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>National, prospective, single-center, double-blind, parallel group, randomized, controlled, interventional Trial.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in subjects´ minimal-erythema-dose (MED).</measure>
    <time_frame>2 weeks</time_frame>
    <description>The MED is the minimal erythema dose, meaning the minimal dose of energy (in this case provided by UV-exposition) per area that leads to a clinically visible skin reaction, mainly a slight reddening.&#xD;
The MED is assessed by a clinical tool called the light-stair.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of excretion of pyrimidine-dimers (PD) in urine.</measure>
    <time_frame>26 days</time_frame>
    <description>Changes from Baseline Visit to Day 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood-serum vitamin-D levels.</measure>
    <time_frame>26 days</time_frame>
    <description>Changes from Baseline Visit to Day 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure.</measure>
    <time_frame>26 days</time_frame>
    <description>Changes from Baseline Visit to Day 24</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in electrolytes (Na+, K+)</measure>
    <time_frame>26 days</time_frame>
    <description>Changes from Baseline Visit to Day 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in kidney function (eGFR)</measure>
    <time_frame>26 days</time_frame>
    <description>Changes from Baseline Visit to Day 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood count</measure>
    <time_frame>26 days</time_frame>
    <description>Changes from Baseline Visit to Day 24</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Photosensitivity</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intake of HCT 25 mg, 1 tablet/d for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intake of Placebo, 1 tablet/d for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Please see arm descriptions</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Please see arm descriptions</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is willing and able to participate and provides written informed consent;&#xD;
&#xD;
          2. Healthy subjects with no concomitant medical conditions;&#xD;
&#xD;
          3. Age ≥ 18 years;&#xD;
&#xD;
          4. The subject is willing to take HCT 25 mg a day although not clinically indicated;&#xD;
&#xD;
          5. The subject is willing to undergo controlled UV-exposition although not clinically&#xD;
             indicated;&#xD;
&#xD;
          6. Skin type I - IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any cardiac disease;&#xD;
&#xD;
          2. History of any dermatologic disease;&#xD;
&#xD;
          3. Renal insufficiency (eGFR &lt;60 ml/min/1.73m²);&#xD;
&#xD;
          4. Intake of photosensitive substances, especially intake of HCT;&#xD;
&#xD;
          5. Frequent, above-average, UV exposition (naturally or artificially);&#xD;
&#xD;
          6. Known hypertension;&#xD;
&#xD;
          7. Known electrolyte disbalance;&#xD;
&#xD;
          8. Systolic blood pressure at baseline &lt;100 mmHg;&#xD;
&#xD;
          9. Skin type V and VI;&#xD;
&#xD;
         10. History of severe diseases, which could endanger the safety of study participant;&#xD;
&#xD;
         11. Known unresolved history of alcohol dependency or drug abuse or any other kind of&#xD;
             dependencies&#xD;
&#xD;
         12. Intake of any of the following medications or substances: Betablockers; nitrates;&#xD;
             barbiturates; phenothiazines; tricyclic antidepressants; vasodilatory drugs;&#xD;
             ACE-inhibitors; NSAIDs; salicylates; phenytoin; Insulin; oral antidiabetic drugs;&#xD;
             vasoconstrictors; glycosides; substances lowering blood-urea levels; substances&#xD;
             causing a Long-QT-Syndrome; chinidine; carbamazepine; cyclosporine; cholecalciferol;&#xD;
             potassium salts; amantadine; allopurinol; methyldopa; cholestyramine; colestipol;&#xD;
             other diuretics; lithium; cytostatic drugs;&#xD;
&#xD;
         13. Women in childbearing age and not using medically acceptable effective contraception&#xD;
             refer to CTFG: The study population includes female of childbearing potential. Female&#xD;
             of childbearing potential have to agree to comply with the applicable contraceptive&#xD;
             requirements of the protocol for the duration of the study or having post-menopausal&#xD;
             status or be permanently sterilized (at least 6 weeks post-sterilization). Highly&#xD;
             effective contraception is defined as a contraceptive method with failure rate of less&#xD;
             than 1 % per year when used consistently and correctly and when applicable, in&#xD;
             accordance with the product label;&#xD;
&#xD;
         14. Subject is pregnant (e.g., positive ß-hCG test) or is breast feeding;&#xD;
&#xD;
         15. Hypersensitivity to the active substance, to HCT or any of its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Mahfoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saarland University Hospital</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-hydrochlorothiazid.html</url>
    <description>Hydrochlorothiazid - Risiko von nichtmelanozytärem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom): Rote-Hand-Brief vom 17. Oktober 2018.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Photosensitivity Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

